Trials / Completed
CompletedNCT03926585
Variations in the DIO2 and MCT10 Genes and Effect of Triiodothyronine Treatment
Longtime Effect of Combination Treatment With L-thyroxine (L-T4) and Liothyronine (L-T3) in Patients With Persistent Hypothyroid Symptoms - Relation to Polymorphisms (SNP) in the DIO2 and the MCT10 Gene
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 82 (actual)
- Sponsor
- Birte Nygaard · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Hypothesis: Variations in the deiodinase 2 gene and monocarboxylate transporter 10 gene is associated with improvement in quality of life after initiation of combination therapy with L-Thyroxine and Liothyronine in patients with persistent hypothyroid symptoms despite conventional L-thyroxine mono-therapy. Purpose: To re-test this hypothesis in patients with continued perceived effect of Liothyronine treatment at least one year after initiation in a patient population more representing of daily clinical practice. The study will help determine whether testing of specific gene variations might predict longtime effect of combination therapy.
Conditions
Timeline
- Start date
- 2019-04-23
- Primary completion
- 2022-08-01
- Completion
- 2022-08-01
- First posted
- 2019-04-24
- Last updated
- 2023-05-25
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT03926585. Inclusion in this directory is not an endorsement.